Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first ...

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025 July 27, 2025, 10:31 pm EDT Share Resize ...

ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight ...

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025 Read Next Valenzuela cancels afternoon in-person classes in public and private kinder, senior high schools July 28, ...

This format may improve patient compliance and comfort. OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising ...

The poster presentation schedule will be available on the Symposium website no later than Friday, July 25. Presenters need to be available for public discussion of your research during one of the ...

Forward-looking statements, including those about BriaCell presenting clinical data presentations at the ESMO Congress 2025; and the contents of all such presentations are based on BriaCell’s current ...

Forward-looking statements, including those about BriaCell presenting clinical data presentations at the ESMO Congress 2025; and the contents of all such presentations are based on BriaCell’s ...

On July 8, OPKO Health, Inc. (NASDAQ:OPK) in collaboration with Entera Bio Ltd. (NASDAQ: ENTX) announced the selection of their Oral GLP-2 Analog for a poster presentation at the 47th European ...